AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00059852
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00536575
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Level 1: Bortezomib 1.3mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 2: Bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 3: Bortezomib 1.6mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.
Trial: NCT00536575
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Levels 1 and 2: 200 mg by mouth twice daily~Dose Level 3: 400 mg by mouth twice daily
Trial: NCT03445195
Drug: Sulbactam-ETX2514
DrugBank: Sulbactam (DB09324)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
Trial: NCT03445195
Drug: Imipenem-cilastatin
RxNorm normalized name: imipenem-cilastatin
DrugBank: Cilastatin (DB01597)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
Trial: NCT00261196
Drug: Collagenase
RxNorm normalized name: Collagenase
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anterior shoulder capsule injection
Trial: NCT01235221
Drug: BIIB041 (Fampridine-SR)
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg twice a day (BID) sustained-release (SR) tablets by mouth for up to 27 months (in addition to treatment in previous studies) or until the product is commercially available, whichever comes first. Doses of study treatment must be spaced at least 12 hours apart.
Trial: NCT01617577
Drug: G-CSF; filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The drug is administered s.c. at a dose of 10 microg/kg daily for 5 days
Trial: NCT00851487
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Amoxicillin 15 mg/kg/dose 8 hourly
Trial: NCT04377295
Drug: Ranibizumab 0.5Mg/0.05Ml Oph Inj
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML OPH INJ
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients received one monthly intravitreal injection of Ranibizumab (0.5 mg/0.05 ml) through the pars plana under aseptic conditions until maximum visual acuity was achieved and there was no sign of macular edema at optical coherence tomography
Trial: NCT04552613
Drug: EGFR-TKI
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (A) Standard programme group, EGFR-TKI targeted therapy;
Trial: NCT04552613
Drug: EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
Trial: NCT03405207
Drug: Vitamin D3 50000 UNT Oral Capsule
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holick's protocol of treating vitamin D deficiency lasting for 8 weeks
Trial: NCT00834041
Drug: Aliskiren 3.125 mini-tablets
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral mini-tablets (3.125 mg) of aliskiren once each morning
Trial: NCT02888054
Drug: lesinurad/allopurinol 200/300 FDC tablet
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02888054
Drug: lesinurad 200 mg
RxNorm normalized name: lesinurad 200 MG
DrugBank: Lesinurad (DB11560)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02888054
Drug: allopurinol 300 mg
RxNorm normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04005768
Drug: Hydroxychloroquine Sulphate
RxNorm normalized name: Hydroxychloroquine sulphate
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
Trial: NCT00367926
Drug: American ginseng root / polysaccharides
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01866254
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 100 mcg hydromorphone into the intrathecal space
Trial: NCT01866254
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 200 mcg of intrathecal morphine
Trial: NCT00779740
Drug: mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
Trial: NCT00779740
Drug: mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
Trial: NCT03557853
Drug: Golimumab Injection
RxNorm normalized name: golimumab Injection
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simponi (golimumab) in fixed dose of 50 mg sc per month according to local label and local clinical practice.
Trial: NCT01058655
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01058655
Drug: Tivozanib
RxNorm normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02154074
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhale Isoflurane 1.5MAC
Trial: NCT02154074
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
Trial: NCT01172522
Drug: Fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine 1%
Trial: NCT04537429
Drug: Eptinezumab
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: up to four iv infusions of eptinezumab
Trial: NCT00003052
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003052
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03060005
Drug: Tears Naturale Forte
RxNorm normalized name: Tears Naturale Forte
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This medication is used to relieve dry, irritated eyes
Trial: NCT03060005
Drug: liposic
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.
Trial: NCT00884442
Drug: Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg nifedipine
Trial: NCT00884442
Drug: Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg nifedipine
Trial: NCT00623103
Drug: Rivastigmine capsule
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine capsules orally twice a day. Target dose 12 mg/day.
Trial: NCT00623103
Drug: Rivastigmine transdermal patch
RxNorm normalized name: rivastigmine Transdermal Product
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm\^2/day delivering 9.5 mg over a 24 hour period.
Trial: NCT03146377
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2 IV on day 1 of a 2-week cycle
Trial: NCT03146377
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 165 mg/m2 IV on day 1 of a 2-week cycle
Trial: NCT04569656
Drug: hydrolyzed guar gum
RxNorm normalized name: Partially Hydrolyzed Guar Gum Oral Powder for Suspension
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg for 6 weeks
Trial: NCT04203498
Drug: Nabiximols
RxNorm normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
Trial: NCT05283278
Drug: Lactoferrin Bovine
RxNorm normalized name: lactoferrin, bovine
DrugBank: Lactoferrin (DB16555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day starting from birth to the 30th day of life for neonates in group A
Trial: NCT01474083
Drug: GK1-399 (formerly TTP399)
RxNorm normalized name: Lor-253(former code)
DrugBank: APTO-253 (DB17143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: GK1-399 200 mg. Oral administration, twice per day.
Trial: NCT01474083
Drug: GK1-399 (formerly TTP399)
RxNorm normalized name: Lor-253(former code)
DrugBank: APTO-253 (DB17143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B: GK1-399 800 mg. Oral administration, once per day.
Trial: NCT01474083
Drug: GK1-399 (formerly TTP399)
RxNorm normalized name: Lor-253(former code)
DrugBank: APTO-253 (DB17143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C: GK1-399 800 mg. Oral administration, twice per day.
Trial: NCT01567930
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intervention: Temsirolimus IV Eligible patients will receive temsirolimus IV on days 1,8,15 every 21 days. Treatment will continue till disease progression or untolerable side effects
Trial: NCT04203797
Drug: dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pre-filled syringe administered by subcutaneous (SC) injections
Trial: NCT02433457
Drug: CC-292
RxNorm normalized name: BTK inhibitor CC-292
DrugBank: Spebrutinib (DB11764)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02433457
Drug: Oral Omeprazole (OMP)
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01407822
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
Trial: NCT01407822
Drug: Gemcitabine/cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
Trial: NCT03844932
Drug: ST-0529
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.
Trial: NCT01235689
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.
Trial: NCT02481583
Drug: Levosulpiride
RxNorm normalized name: levosulpiride
DrugBank: Levosulpiride (DB16021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: different formulations of levosulpiride
Trial: NCT00119431
Drug: C1 inhibitor concentrate
RxNorm normalized name: C1 INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02195336
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.
Trial: NCT02195336
Drug: paclitaxel and carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
Trial: NCT01888757
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
Trial: NCT02106507
Drug: apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: apalutamide, 240 mg/day, oral
Trial: NCT02106507
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended
Trial: NCT00098878
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00881270
Drug: LACTIC ACID(ND)
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dermacyd Infantile (LACTIC ACID)
Trial: NCT02339766
Drug: Intrathecal Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.
Trial: NCT00289601
Drug: eptifibatide
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04069858
Drug: Switching to Generic Entecavir (Baracle®)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: switching to Baracle® 1 mg (generic drug) in chronic hepatitis B patients taking Baraclude® 1 mg (brand drug)
Trial: NCT00612235
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects had at least 3 months on a stable dosage of lamotrigine monotherapy.
Trial: NCT00612235
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects had at least 3 months on a stable dosage of levetiracetam monotherapy.
Trial: NCT00612235
Drug: Carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects had at least 3 months on a stable dosage of carbamazepine monotherapy.
Trial: NCT01054508
Drug: nicotinic acid/laropiprant
DrugBank: Laropiprant (DB11629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
Trial: NCT01141725
Drug: bendamustine hydrochloride
RxNorm normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01141725
Drug: idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04049864
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.
Trial: NCT00662025
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib 37.5 mg daily, continuous dosing
Trial: NCT00539877
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postoperative day 1, IP CPT-11 chemotherapy will be given by CAPD catheter. CPT-11 in 1L of normal saline, prewarmed to 37°C will be given intraperitoneally.~If there is no DLT and patients agree with the treatment, patients can receive 3 more times of IP chemotherapy with same dose of CPT-11 at 3 weeks interval. After total 4 cycles of IP chemotherapy, peritoneal disease will be reassessed with abdominal-pelvis CT. Pharmacokinetic study is not planned with this treatment.
Trial: NCT00528242
Drug: SLx-2101
RxNorm normalized name: SLx-2101
DrugBank: SLx-2101 (DB05615)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00246623
Drug: Exubera (inhaled insulin)
RxNorm normalized name: insulin human, rDNA origin Inhalation Powder [Exubera]
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00379457
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00379457
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00379457
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00379457
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00379457
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00379457
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00194740
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2, IV, day 1 of each 21 day cycle
Trial: NCT00194740
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 27.5 mg/m2, IV, days 8 \& 15 of each 21 day cycle
Trial: NCT00194740
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
Trial: NCT00930865
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, 10 mg. Single Dose, 7 Days
Trial: NCT03967249
Drug: IONIS GHR-LRx
RxNorm normalized name: IONIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IONIS GHR-LRx by subcutaneous injection.
Trial: NCT03967249
Drug: Somatostatin Receptor Ligand (SRL)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Somatostatin Receptor Ligand (lanreotide, octreotide) once monthly.
Trial: NCT00670956
Drug: Betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 mg intramuscularly x 2 doses 24 hours apart
Trial: NCT01601509
Drug: Nasal tramazoline with dexamethazone
RxNorm normalized name: dexamethasone / tramazoline Nasal Spray
DrugBank: Tramazoline (DB13064)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.